# Retatrutide Trial Evidence: Phase 1 Through Phase 3 Research Findings > Retatrutide Phase 1, 2, and 3 trial results reviewed in full — mechanism, efficacy figures, safety profile, and the TRIUMPH Phase 3 program. Every finding cited. Phase 1b pharmacokinetics, Phase 2 obesity and diabetes results, liver disease data, structural biology, and the ongoing TRIUMPH program — with every quantitative figure traced to its primary source. ## Before the details This page reviews the clinical research on retatrutide, an investigational drug that is not yet approved anywhere in the world. It is still running Phase 3 trials as of 2026 — the large, final-stage studies needed before a company can apply for regulatory approval. Retatrutide targets three hormones at once: GLP-1, GIP, and glucagon (a hormone that raises blood glucose and increases the body's calorie-burning). That triple-target design is what researchers believe drives its unusually large weight-loss results. The main benefit found in trials is substantial weight reduction. The main risks are GI side effects and a dose-related increase in resting heart rate. Long-term effects are still being studied. Nothing on this page is a recommendation — it is a plain-English review of what controlled trials have measured. ## Mechanism: how retatrutide works at the receptor level Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide engineered to simultaneously activate three hormone receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). All three are class-B GPCRs — a family of proteins embedded in cell membranes that respond to peptide hormones by activating intracellular cAMP/PKA signaling cascades. GLP-1R activation suppresses appetite and slows gastric emptying. GIPR activation enhances post-meal insulin secretion and influences adipose (fat) tissue metabolism. GCGR activation raises hepatic fat breakdown and increases resting energy expenditure — the mechanism that makes retatrutide a thermogenic compound, not just an appetite suppressant. Cryo-EM structural studies published in 2024 resolved retatrutide's simultaneous binding at all three receptors at high resolution (2.68, 3.26, and 2.84 angstrom). These structures confirmed that retatrutide is approximately 8.9 times more potent at GIPR than native GIP, while being somewhat less potent than native hormones at GCGR (0.3x) and GLP-1R (0.4x) [3]. A note on terminology: retatrutide is sometimes called a "GLP-3 agonist" in casual use — this is a misnomer. There is no GLP-3 receptor; retatrutide is a triple GLP-1/GIP/glucagon agonist. The fatty-acid modification (C20 fatty-diacid acylation) causes the peptide to bind reversibly to albumin, the main protein in blood, which is what extends its half-life to approximately 6 days and makes once-weekly dosing pharmacologically sound [4]. ## Phase 1b: first-in-human pharmacokinetics and early efficacy The first-in-human data for retatrutide were published in the Lancet in 2022. The Phase 1b trial enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) and studied escalating once-weekly subcutaneous doses over 12 weeks [4]. Key pharmacokinetic finding: half-life was approximately 6 days, confirming the once-weekly dosing rationale. Efficacy signal: at the highest dose group, placebo-adjusted weight loss was 8.96 kg (90% CI: -11.16 to -6.75 kg). Daily glucose fell by 2.8 mmol/L at 3 mg. Treatment-emergent adverse events (TEAEs) occurred in 63% of participants, predominantly GI effects. The investigators described the safety profile as acceptable and the compound warranted advancement to Phase 2. ## Phase 2 obesity trial: the -24.2% finding The landmark Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity or overweight with at least one metabolic comorbidity. Participants received once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, for 48 weeks [1]. At 48 weeks, mean body-weight change at 12 mg was -24.2% versus -2.1% in the placebo group. The dose-response was clear: 1 mg produced -8.7%, 4 mg produced -17.3%, 8 mg produced -22.8%, and 12 mg produced -24.2%. GI adverse events were dose-related and predominantly mild-to-moderate in severity. Discontinuation due to adverse events was 18% at 12 mg, primarily from GI effects. A dose-dependent increase in heart rate peaked at approximately 24 weeks then partially plateaued. A substudy of 98 participants with metabolic dysfunction-associated steatotic liver disease (MASLD — fatty liver linked to metabolic risk factors) found that 12 mg reduced liver fat by 82.4% at 24 weeks (measured by MRI-PDFF, a non-invasive scan for liver fat), with 86% of participants reaching normal liver fat levels. Reductions were sustained to 48 weeks (-86.0% at 12 mg) [5]. ## Phase 2 type 2 diabetes trial A parallel Phase 2 trial in type 2 diabetes, published in the Lancet in 2023, enrolled 281 adults with inadequately controlled type 2 diabetes (HbA1c 7.5–11%) [2]. Participants received escalating doses from 0.5 to 12 mg once weekly over 36 weeks. At 24 weeks, HbA1c fell by 2.02% in the 12 mg group versus 0.01% in placebo. At 36 weeks, body weight fell by 16.94% versus 3.00% in placebo. Mild-to-moderate GI adverse events occurred in approximately 35% of participants. No deaths were reported; no severe hypoglycemia occurred in participants not on background insulin. A 2026 network meta-analysis that pooled results across glucagon-receptor agonist trials found retatrutide ranked highest for both weight reduction and HbA1c reduction versus placebo [13]. ## Phase 3 (TRIUMPH program): early results Eli Lilly's TRIUMPH Phase 3 program includes multiple trials covering obesity, type 2 diabetes, cardiovascular outcomes, and chronic kidney disease. The first Phase 3 readout, TRANSCEND-T2D-1, was published in the Lancet in 2026. It enrolled 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone [12]. Over 40 weeks, retatrutide 12 mg reduced HbA1c by 1.94% and body weight by 15.3%, compared with 0.81% HbA1c reduction and 2.6% weight reduction in the placebo group. Adverse events were predominantly mild-to-moderate GI in nature. No severe hypoglycemia was reported in this monotherapy population. Dedicated cardiovascular and renal outcomes trials remain ongoing. A 2025 evidence review characterized the triple GLP-1/GIP/glucagon agonist class as demonstrating "the highest achievable weight loss with pharmacotherapy" and expected the biochemical and weight-loss outcomes to translate into cardiometabolic benefit [7] — though that translation remains to be confirmed in outcomes trials. ## Cardiac effects: the inotropic data Beyond heart-rate increases, 2026 research in isolated human atrial preparations found that retatrutide elevated cardiac force of contraction in a concentration-dependent manner. The effect was potentiated by a PDE-III inhibitor and blocked by antagonists of all three receptors (GLP-1R, GIPR, GCGR) but not by a beta-blocker [8]. This mechanistic work confirms that retatrutide's cardiac effects are receptor-mediated and multi-pathway. The clinical significance of these inotropic effects in intact humans taking therapeutic doses is not yet established. A dedicated cardiovascular outcomes trial is ongoing. People with pre-existing arrhythmias, tachycardia, or heart disease represent a population where the heart-rate and inotropic effects of retatrutide deserve particular attention, and where clinical oversight would be essential. --- Plain-language reviews of published investigational trial evidence — not a clinical service, not a vendor, not an endorsement.